达格列净联合二甲双胍治疗2型糖尿病的临床研究

汪庆飞; 许健; 骆玲莉

doi:10.16766/j.cnki.issn.1674-4152.004031

达格列净联合二甲双胍治疗2型糖尿病的临床研究

doi: 10.16766/j.cnki.issn.1674-4152.004031

1.
蚌埠医科大学第二附属医院药剂科，安徽蚌埠 233040
2.
蚌埠医科大学第一附属医院药剂科，安徽蚌埠 233004
3.
安徽医科大学临床药理研究所，安徽合肥 230032

基金项目:

安徽高校自然科学研究项目 KJ2021A0801

详细信息

通讯作者:
汪庆飞，E-mail：181519544@qq.com

中图分类号: R587.1
计量
- 文章访问数: 26
- HTML全文浏览量: 6
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2024-09-19
- 网络出版日期: 2025-09-04

Clinical study of dapagliflozin in combination with metformin for moderate to severe the type 2 diabetes mellitus

1.
Department of Pharmacy, the Second Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233040, China

摘要

摘要: 目的探讨2型糖尿病患者采用达格列净联合二甲双胍治疗对稳定控制血糖、减少并发症的临床应用效果，为2型糖尿病的临床治疗提供参考。方法选取2021年6月—2023年5月蚌埠医科大学第二附属医院收治的2型糖尿病住院患者80例，其中40例联合给药，即服用达格列净联用二甲双胍，作为实验组；另40例采取单一给药，即仅服用二甲双胍，作为对照组。比较2组治疗效果, 包括治疗前后血糖控制指标[糖化血红蛋白(HbA1c)、空腹血糖(FBG)、空腹C肽、餐后1 h C肽]，肾功能指标[血肌酐(Cr)、尿酸(UA)、胱抑素C(CysC)]，观察2组患者不良反应发生情况。结果实验组患者治疗有效率为92.5%(37/40), 明显高于对照组[75.0%(30/40), P＜0.05]。实验组治疗前后HbA1c、空腹血糖、空腹C肽、餐后1 h C肽比较差异有统计学意义(P＜0.05)；实验组治疗前后肾功能指标(Cr、UA、CysC)比较差异有统计学意义(P＜0.05)。实验组不良反应发生率明显低于对照组[17.5%(7/40) vs. 50.0%(20/40), P＜0.05]。结论达格列净联合二甲双胍治疗2型糖尿病效果较单一使用二甲双胍更好, 可降低患者血糖, 减少不良反应，明显改善患者肾功能。
- 2型糖尿病 /
- 达格列净 /
- 二甲双胍 /
- 联合治疗
Abstract: Objective To investigate the clinical effects of treatment with dapagliflozin plus metformin in patients with type 2 diabetes on stable control of blood glucose and reducing complications, to provide a reference for the clinical treatment of type 2 diabetes mellitus. Methods A total of 80 patients with type 2 diabetes admitted to the Second Affiliated Hospital of Bengbu Medical University from June 2021 to May 2023 were selected, of which 40 patients received dagaglizin combined with metformin as the experimental group. Another 40 patients were given a single dose, that is, metformin alone, as a control group. The therapeutic effects of the two groups were compared, and the blood glucose control indexes before and after treatment were as follows: glycated hemoglobin A1c (HbA1c), fasting blood glucose (FBG), fasting C-peptide, and 1 h postprandial C-peptide. Renal function indexes of patients were as folows: serum creatinine (Cr), uric acid (UA), cystatin C (CysC). Clinical therapeutic effects and adverse reactions of patients in two groups were observed after different treatment methods. Results The effective rate of treatment in the test group was 92.5% (37/40), which was significantly higher than that in the control group [75.0% (30/40), P < 0.05]. The results of HbA1c, FBG, fasting C-peptide, and 1 h postprandial C-peptide in the experimental group were significantly different before and after treatment (P < 0.05). The renal function indexes (Cr, UA, CysC) of the experimental group were significantly different before and after treatment (P < 0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group [17.5% (7/40) vs. 50.0% (20/40), P < 0.05]. Conclusion In the treatment of type 2 diabetes mellitus, dagaglizin combined with metformin has a better effect than metformin alone, which can reduce blood glucose and adverse reactions in patients and significantly improve kidney function of patients.
- Type 2 diabetes mellitus /
- Dapagliflozin /
- Metformin /
- Combination therapy

HTML全文

表 1 2组糖尿病患者治疗总有效率比较[例(%)]

Table 1. Comparison of the total effective rate of treatment between the two groups of diabetic patients [cases (%)]

组别	例数	显效	有效	无效	总有效
对照组	40	21(52.5)	9(22.5)	10(25.0)	30(75.0)
实验组	40	25(62.5)	12(30.0)	3(7.5)	37(92.5)
注：2组总有效率比较，χ²=4.501, P=0.034。

下载: 导出CSV

表 2 2组糖尿病患者治疗前后HbA1c、空腹血糖、空腹C肽、餐后1 h C肽比较(x±s)

Table 2. Comparison of HbAlc, fasting blood glucose, fasting C-peptide, and postprandial 1-hour C-peptide between the two groups of diabetic patients before and after treatment (x±s)

组别	例数	HbA1c(%)		空腹血糖(mmol/L)		空腹C肽(ng/mL)		餐后1 h C肽(ng/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	40	9.47±2.21	7.90±1.32^b	9.74±1.54	7.70±1.83^b	5.36±1.45	2.16±0.52^b	15.10±3.16	12.50±2.98^b
实验组	40	9.76±1.82	6.40±1.34^b	10.30±2.42	5.34±1.29^b	5.26±1.76	3.69±0.87^b	14.80±3.05	9.66±2.47^b
统计量		0.635^a	5.058^c	1.229^a	6.659^c	0.284^a	9.506^c	0.432^a	4.640^c
P值		0.527	＜0.001	0.223	＜0.001	0.777	＜0.001	0.667	＜0.001
注：^a为t值，^c为F值。与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 3 2组糖尿病患者治疗前后肾功能指标比较(x±s)

Table 3. Comparison of renal function indicators between the two groups of diabetic patients before and after treatment (x±s)

组别	例数	Cr(μmol/L)		UA(μmol/L)		CysC(mg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	40	94.6±7.99	83.3±10.8^b	391.4±59.7	360.2±87.6^b	2.10±0.36	1.88±0.52^b
实验组	40	92.0±20.6	49.5±13.9^b	388.4±87.5	245.5±39.6^b	2.04±0.65	1.05±0.23^b
统计量		0.744^a	12.144^c	0.179^a	7.546^c	0.509^a	9.194^c
P值		0.460	＜0.001	0.858	＜0.001	0.613	＜0.001
注：^a为t值，^c为F值。与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

参考文献(18)

[1]	丁晓洁, 张永明, 宋海燕, 等. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(6): 815-818. doi: 10.3969/j.issn.1672-5069.2023.06.012 DING X J, ZHANG Y M, SONG H Y, et al. Changes of NLR and PLR in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease and their clinical significance[J]. Journal of Practical Hepatology, 2023, 26(6): 815-816. doi: 10.3969/j.issn.1672-5069.2023.06.012
[2]	张蓓, 薛青霞, 陈娇娇, 等. 钠-葡萄糖协同转运蛋白2抑制剂临床综合评价方法研究[J]. 中国医院用药评价与分析, 2023, 23(4): 502-505. ZHANG B, XUE Q X, CHEN J J, et al. Clinical comprehensive evaluation of sodiumglucose cotransporter 2 inhibitors[J]. Chinese Hospital Drug Evaluation and analysis, 2023, 23(4): 502-505.
[3]	王瑶, 姚丽琴. 达格列净联合利拉鲁肽治疗2型糖尿病的临床研究[J]. 糖尿病新世界, 2021, 24(14): 49-52, 56. WANG Y, YAO L Q. Clinical study of dagliaglizin combined with liraglutide in the treatment of type 2 diabetes mellitus[J]. Diabetes New World, 2021, 24(14): 49-52, 56.
[4]	李春, 彭慧芳, 张颖裕. 洛塞那肽联合达格列净治疗早期2型糖尿病肾病的临床疗效及对血糖水平和肾功能的影响[J]. 中国合理用药探索, 2023, 20(11): 79-84. LI C, PENG H F, ZHANG Y Y. Clinical efficacy of losenatide combined with dagliprazin in the treatment of early type 2 diabetic nephropathy and its effect on blood glucose level and renal function[J]. Drugs for diabetes, 2023, 11(20): 79-84.
[5]	仕鸿, 陈永泽, 麦振华, 等. 基于粒子群优化算法BP神经网络的2型糖尿病危险因素分析及筛查模型构建[J]. 华西医学, 2024, 39(2): 251-258. WANG S H, CHEN Y Z, MAI Z H, et al. Risk factor analysis and screening model construction of type 2 diabetes based on BP neural network based on particle swarm optimization algorithm[J]. Chinese Journal of Medicine, 2024, 39(2): 251-258.
[6]	李靖, 周玉森, 郝树立, 等. 2型糖尿病患者营养风险筛查及其影响因素分析[J]. 中华全科医学, 2024, 22(1): 74-76. doi: 10.16766/j.cnki.issn.1674-4152.003334 LI J, ZHOU Y S, HAO S L, et al. Nutritional risk screening and its influencing factors in patients with type 2 diabetes mellitus[J]. Chinese Journal of General Medicine, 2024, 22(1): 74-76. doi: 10.16766/j.cnki.issn.1674-4152.003334
[7]	陆益平, 刘远洋, 叶嘉焕, 等. 基于组分中药理论的薏苡仁知母药对治疗糖尿病患者的配伍特点[J]. 世界中医药, 2024, 19(9): 1334-1338. doi: 10.3969/j.issn.1673-7202.2024.09.020 LU Y P, LIU Y Y, YE J H et al. Compatibility characteristics of Coiren Zhimu drug in the treatment of diabetic patients based on the theory of component Chinese medicine[J]. World of Chinese Medicine, 2024, 19(9): 1334-1338. doi: 10.3969/j.issn.1673-7202.2024.09.020
[8]	ZHOU T T, XU X, DU M F, et al. A preclinical overview of metformin for the treatment of type 2 diabetes[J]. Biomed Pharmacother, 2018, 106: 1227-1235. doi: 10.1016/j.biopha.2018.07.085
[9]	李慕白, 王婷婷, 张多加, 等. 小檗碱改善多囊卵巢综合征伴胰岛素抵抗大鼠子宫组织局部胰岛素抵抗的作用机制研究[J]. 现代中西医结合杂志, 2022, 31(2): 153-160, 202. doi: 10.3969/j.issn.1008-8849.2022.02.002 LI M B, WANG T T, ZHANG D J, et al. Effect of berberine on local insulin resistance in uterus of rats with polycystic ovary syndrome and insulin resistance[J]. Journal of Modern Integrated Chinese and Western Medicine, 2022, 31(2): 153-160, 220. doi: 10.3969/j.issn.1008-8849.2022.02.002
[10]	何卫东, 杨柳清, 衡先培, 等. 丹瓜方对糖尿病大鼠胰腺形态及GLUT4、LEP表达的影响[J]. 辽宁中医药大学学报, 2022, 24(12): 5-9. HE W D, YANG L Q, HENG X P, et al. Effects of Dangguafang on pancreatic morphology and GLUT4 and LEP expression in diabetic rats[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2022, 24(12): 5-9.
[11]	张倩, 邵亚丽, 牛芳圆. 达格列净联合利拉鲁肽对2型糖尿病患者代谢指标的影响研究[J]. 中国处方药, 2024, 22(2): 108-111. ZHANG Q, SHAO Y L, NIU F Y. Effect of dagliprazin combined with Liraglutide on metabolic indexes in patients with type 2 diabetes mellitus[J]. Chinese Prescription Drugs, 2024, 22(2): 108-111.
[12]	余荷花. 达格列净联合二甲双胍治疗初诊2型糖尿病患者的临床效果[J]. 临床合理用药, 2024, 17(8): 95-97, 104. YU H H. Clinical effect of Dapaglizin combined with metformin in treatment of newly diagnosed patients with type 2 diabetes mellitus[J]. Journal of Clinical Rational Use of Drugs, 2024, 17(8): 95-97, 104.
[13]	姚海峰, 王凤玲, 何勇. 带量采购政策下池州市某三级综合医院口服降糖药使用情况分析[J]. 华南预防医学, 2023, 49(12): 1563-1567. YAO H F, WANG F L, HE Y. Analysis on the use of oral hypoglycemic drugs in a tertiary general hospital in Chizhou City under the policy of purchasing quantity[J]. South China Preventive Medicine, 2023, 49(12): 1563-1567.
[14]	李茂, 罗定兰. 达格列净对单用二甲双胍血糖控制不佳2型糖尿病患者的疗效及氧化应激的影响[J]. 临床内科杂志, 2021, 38(10): 678-681. doi: 10.3969/j.issn.1001-9057.2021.10.009 LI M, LUO D L. Effects of daglipzin on oxidative stress in patients with type 2 diabetes mellitus with poor glycemic control by metformin alone[J]. Journal of Clinical Internal Medicine, 2021, 38(10): 678-681. doi: 10.3969/j.issn.1001-9057.2021.10.009
[15]	甄淑贤, 黄运通, 司徒瑞娴. 二甲双胍联合达格列净对2型糖尿病的疗效分析及对胰岛功能的影响[J]. 哈尔滨医药, 2022, 42(3): 56-57. doi: 10.3969/j.issn.1001-8131.2022.03.023 ZHEN S X, HUANG Y T, SITU R X. Effect of metformin combined with Daglipzin on type 2 diabetes mellitus and its effect on islet function[J]. Harbin Medicine, 2022, 42(3): 56-57. doi: 10.3969/j.issn.1001-8131.2022.03.023
[16]	张颖, 杨文奇. 达格列净对老年2型糖尿病合并射血分数保留型心力衰竭的疗效观察[J]. 航空航天医学杂志, 2024, 35(1): 11-15. ZHANG Y, YANG W Q. Therapeutic effect of dagaglizin on elderly patients with type 2 diabetes mellitus complicated with ejection fraction preserving heart failure[J]. Journal of Aerospace Medicine, 2024, 35(1): 11-15.
[17]	郭彩霞, 胡颖, 许素红, 等. 度拉糖肽联合达格列净和替米沙坦治疗糖尿病合并心肾功能不全的效果分析[J]. 实用临床医药杂志, 2023, 27(20): 118-121, 126. GUO C X, HU Y, XU S H, et al. Effect of Duragtide combined with daglipin and Telmisartan in the treatment of diabetic patients with cardiac and renal dysfunction[J]. Journal of Practical Clinical Medicine, 2023, 27(20): 118-121, 126.
[18]	裴改改, 肖浩, 张云峰, 等. 达格列净联合维格列汀治疗2型糖尿病老年患者的效果[J]. 中国药物滥用防治杂志, 2023, 29(2): 324-328. PEI G G, XIAO H, ZHANG Y F, et al. Efficacy of daglipzin combined with vigagliptin in the treatment of elderly patients with type 2 diabetes mellitus[J]. Chinese Journal of Drug Abuse Prevention, 2023, 29(2): 324-328.